These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16645328)

  • 21. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
    Budman DR; Calabro A
    Breast Cancer Res Treat; 2002 Jul; 74(1):41-6. PubMed ID: 12150451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.
    Pu H; Zhang Q; Zhao C; Shi L; Wang Y; Wang J; Zhang M
    Pathol Oncol Res; 2018 Jul; 24(3):557-565. PubMed ID: 28744693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
    Hassan BA; Yusoff ZB; Hassali MA; Othman SB; Weiderpass E
    Asian Pac J Cancer Prev; 2012; 13(9):4373-8. PubMed ID: 23167346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
    Dhillon S; Lyseng-Williamson KA
    Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells.
    Jeong J; Lee KS; Choi YK; Oh YJ; Lee HD
    J Korean Med Sci; 2011 Dec; 26(12):1569-75. PubMed ID: 22147993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents.
    Budman DR; Calabro A; Kreis W
    Anticancer Drugs; 1998 Sep; 9(8):697-702. PubMed ID: 9823428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.
    Tonyali O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2010 Nov; 11(16):2715-25. PubMed ID: 20977404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.
    Budman DR; Tai J; Calabro A; John V
    Invest New Drugs; 2011 Dec; 29(6):1224-9. PubMed ID: 20533074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Zoledronic acid and bone pathology in the course of neoplasia. Part I].
    Caffo O
    Tumori; 2005; 91(5):22-6. PubMed ID: 16459649
    [No Abstract]   [Full Text] [Related]  

  • 31. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.
    Edelman MJ; Quam H; Mullins B
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):141-4. PubMed ID: 11561780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
    J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.
    Neville-Webbe HL; Coleman RE; Holen I
    Br J Cancer; 2010 Mar; 102(6):1010-7. PubMed ID: 20160726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation.
    Yang C; Davis JL; Zeng R; Vora P; Su X; Collins LI; Vangveravong S; Mach RH; Piwnica-Worms D; Weilbaecher KN; Faccio R; Novack DV
    Cancer Discov; 2013 Feb; 3(2):212-23. PubMed ID: 23269702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyaluronan synthesis inhibitor supplements the inhibitory effects of zoledronic acid on bone metastasis of lung cancer.
    Futamura N; Urakawa H; Arai E; Kozawa E; Ishiguro N; Nishida Y
    Clin Exp Metastasis; 2013 Jun; 30(5):595-606. PubMed ID: 23288481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines.
    Karabulut B; Karaca B; Atmaca H; Kisim A; Uzunoglu S; Sezgin C; Uslu R
    Mol Biol Rep; 2011 Jan; 38(1):249-59. PubMed ID: 20349282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination.
    Sanli UA; Gorumlu G; Erten C; Gul MK; Cengiz E; Kucukzeybek Y; Karaca B; Atmaca H; Uzunoglu S; Karabulut B; Uslu R
    Cell Biol Int; 2009 Nov; 33(11):1165-72. PubMed ID: 19716895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An in Vitro Study.
    Elsayed M; Kobayashi D; Kubota T; Matsunaga N; Murata R; Yoshizawa Y; Watanabe N; Matsuura T; Tsurudome Y; Ogino T; Ohdo S; Shimazoe T
    Biol Pharm Bull; 2016 Aug; 39(8):1238-46. PubMed ID: 27181081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.